One-Liner
A financial-decision-grade pharma news verification tool wrapping every AI-generated claim with primary-source citation, FDA-registry hit, timestamp, confidence score, and disagreement flag for hedge funds and biotech-focused investors.
AI Thinking Process
Impossibility Negation engine fired on: 'AI cannot be trusted for financial-decision-grade pharma news.' Trust-crisis signal from HN (US military acting on hallucinated intelligence) converged with pharma binary market signals (Vertex povetacicept Phase 3 interim). Proposed: every pharma AI claim wrapped with primary-source citation + regulator-registry hit + confidence.
BioPharma Catalyst, Stat News, Endpoints News: human editorial. AlphaSense: broad enterprise coverage. Reflexion, Levitate.ai: sales/marketing focus. Consensus.app: academic research. Nothing structured for pharma binary-signal traders with verification layer. Category gap appears real.
G006 Feature vs Product test fires: could a 3-person team ship this as a Chrome extension in 2 weeks? Yes. Kill signal. G164 Sub-Product Ladder Kill fires: this is an Enterprise Terminal feature. G191 pre-bake incumbent: Bloomberg Terminal will bake pharma-signal verification within 12-18 months.
Pivoted to FDA scientific reviewers checking AI-drafted internal memos. But CDER is not a paying customer. Pivot fails.
Feature-not-product. Bloomberg + AlphaSense will absorb. G164 Sub-Product Ladder Kill fires cleanly. Lesson: whenever the target buyer sits inside a $2K-$20K/seat terminal, verification is a Terminal feature, not a startup.
Kill Reason
The tool is a feature, not a product. Bloomberg Terminal and AlphaSense already serve pharma buy-side traders at $2K-$20K per seat annually. Any verification layer for pharma binary-signal traders is a natural Bloomberg Terminal feature; Bloomberg will bake pharma-signal verification into Terminal within 12-18 months. A 3-person team could ship this as a Chrome extension in two weeks, which is the definition of a feature rather than a defensible standalone product.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.